Breakpoint Therapeutics Gmbh

Ucb Biopharma Sprl

Forge Therapeutics, Inc.

Blacksmith Medicines, Inc.

Ian Yule

Min Teng

David Thomas Puerta

Xiaoming Li

Baskar Nammalwar

Holly Atton

Serge Convers-Reignier

Andrea Guerrero Corella

Jonathan Hollick

Stuart Robert Flanagan

Julien Gilbert Jacques Malassis

Matthew Raymond Smith

Michelle Southey

Alastair Parkes

Adele Faulkner

Christian Perez

John Robert Porter

Rikki Peter Alexander

Daniel Christopher Brookings

Boris Kroeplien

Matthew Duncan Selby

Elizabeth Pearl Jones

Jonathan Bentley

Fabien Claude Lecomte

Gareth Neil Brace

Michael Alan Shaw

James Madden

Prafulkumar Tulshibhai Chovatia

Craig Johnstone

Hervé Jean Claude Deboves

Praful Tulshi Chovatia

Darshan Gunvant Vaidya

Craig Miller

Craig Adrian Miller

Provided herein are heterocyclic derivative compounds and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like.

Antibacterial compounds

The present invention relates to a compound of the Formula: The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

DNA polymerase theta inhibitor for treatment of cancer

The present invention relates to a compound of the Formula: and pharmaceutically salts thereof. The compound of the present invention inhibits Polθ. This novel therapeutic compound is therefore useful for the treatment and/or prevention of diseases and conditions in which Polθ activity is implicated, such as, for example but not limited to, the treatment and/or prevention of cancer. The present invention also relates to pharmaceutical compositions comprising the novel therapeutic compound defined herein, to processes for synthesising the compound and to their use for the treatment of diseases and/or conditions in which Polθ activity is implicated.

Compounds, compositions, and therapeutic uses thereof

Provided herein are heterocyclic derivative compounds of Formula (II), and pharmaceutical compositions comprising said compounds that are useful for inhibiting the growth of gram-negative bacteria. Furthermore, the subject compounds and compositions are useful for the treatment of bacterial infection, such as urinary tract infection and the like. 

A series of substituted benzimidazole, imidazo[1,2-a]pyridine and pyrazolo[1,5-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNF&#x3b1; activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Fused imidazole and pyrazole derivatives as modulators of TNF activity

Growing community of inventors

Abingdon, United Kingdom

Ian Yule